Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal
pharmaphorum
JULY 5, 2021
The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added.
64 
Let's personalize your content